Phase II trial of PCNU in breast carcinoma |
| |
| Authors: | Rubins Jonathan M. Taylor Samul G. |
| |
| Affiliation: | (1) University of Rochester Cancer Center, CA11083 Rochester, NY, USA;(2) Rush-Presbyterian-St. Luke's Medical Center, CA10948 Chicago, IL, USA;(3) Rush Medical College, 1725 W. Harrison Street, Suite 830, 60612 Chicago, IL, USA |
| |
| Abstract: | The Eastern Cooperative Oncology Group undertook a limited institution phase II study of PCNU in advanced, metastatic breast cancer. The study was limited to patients treated with 1 to 2 prior chemotherapy regimens. Accrual goals were 30 patients but the study was terminated after 10 patients had no response, with a rapid time to progression of 4 weeks, despite considerable hematologic toxicity. Based on this experience and negative results in two prior studies in more heavily pretreated patients, we conclude PCNU is inactive in breast cancer.This study was conducted by the Eastern Cooperative Oncology Group, (Paul P. Carbone, M.D., Chairman, CA 21115) and supported by Public Health Institutes of Health, and the Department of Health and Human Services. |
| |
| Keywords: | breast carcinoma advanced chemotherapy PCNU Phase II |
| 本文献已被 SpringerLink 等数据库收录！ |
|
